Targovax to expand on-going phase I/II clinical study CT-TG01-01 with a new group of up to 13 patients.

Oslo, March 9, 2015 Press release no 4 - 2015
 
 
Immunotherapy specialist Targovax's lead candidate TG01, a novel peptide vaccine against cancer specific RAS mutations, is currently being tested in a Phase I/II study in combination with gemcitabine as an  adjuvant treatment in resected pancreatic cancer. The purpose of the trial expansion announced today is to build on the positive findings of the immune responses noted to date to further optimise the TG01 treatment regimen and safety profile of the combination therapy. The submission for regulatory approvals is planned for end of March. 
 
"Although we have already achieved the primary endpoints of the study, we believe that there is a potential for further optimisation of the combination treatment regimen. Potentially this might further improve the immunological effect of TG01 when combined with gemcitabine, as well as reducing the overall number of vaccinations which will enhance the safety profile. Results from the new group of patients will be of great value for us when it later comes to designing our upcoming randomised proof of concept study. Adding a new group of patients in an already on-going study will save us time and money. We aim to start enrolment of patients in May 2015," says Gunnar Gårdemyr, CEO of Targovax.
 
Background:
 
CT TG01-01 is a single arm study testing the peptide based cancer vaccine TG01 in combination with gemcitabine for adjuvant treatment of resected/operated pancreatic cancer. TG01 targets cancer specific RAS mutations in pancreatic cancer. Today gemcitabine is the most frequently used standard of care chemotherapy for pancreatic cancer. The primary objectives of the study are safety and induction of TG01 immune response. Secondary objectives are safety, immune response and observation of survival up to two years. The study is conducted in UK and Norway.
 
 
Contact:
 
Targovax
 
Gunnar Gårdemyr, Chief Executive Officer, Cell phone: (+41) 798 340 585
 
 
Jonas Einarsson, Chairman of the Board, cell phone: +47 48 09 63 55 
E-mail: [email protected]
 
Richard Hayhurst, RH Associates, cell phone (+44) 7711 821527

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.